Medication for opioid use disorder, sometimes called medication-assisted treatment or MAT, is the use of FDA-approved medications to treat opioid use disorder: buprenorphine, methadone, and naltrexone. Methadone gets the most attention because it requires a licensed opioid treatment program, but buprenorphine and naltrexone are the two medications a mobile program can start most easily, because any qualified prescriber can offer them without an opioid treatment program license. That makes them the backbone of mobile MAT and the fastest way to put treatment in reach of people who cannot get to a fixed clinic.
The reason this matters is the size of the access gap. Among adults who needed opioid use disorder treatment in 2022, only 25.1% received medication for it, according to the CDC's Morbidity and Mortality Weekly Report. Buprenorphine and naltrexone let a mobile unit close part of that gap without the licensing weight of methadone. This post explains how each medication works, why buprenorphine fits mobile care so well, how to start treatment at the same visit, and how to keep people connected to ongoing care. For the operating model, see our Behavioral Health Satellite Clinic Network.
Medication for opioid use disorder is treatment that uses FDA-approved medications, combined with counseling and support, to treat the disorder as the chronic medical condition it is. The three medications work in different ways: buprenorphine is a partial agonist, methadone is a full agonist, and naltrexone is an antagonist that blocks opioid effects. These medications save lives. Agonist medications, methadone and buprenorphine, are associated with roughly a 50% reduction in mortality among people with opioid use disorder.
Buprenorphine is a partial opioid agonist: it eases withdrawal and cravings while producing a ceiling effect that lowers overdose risk compared with full agonists. That safety profile, plus its regulatory status, is why it fits mobile care so well. Any qualified prescriber can start it, no opioid treatment program license is required, and it can be prescribed from a mobile unit.
The medication's effect after an overdose is measurable. Opioid overdose deaths fell 38% for people on buprenorphine compared with no MOUD over a 12-month follow-up, according to the National Institutes of Health. Because buprenorphine does not require daily observed dosing the way methadone often does, it fits a weekly or biweekly mobile route, which is what makes it the practical center of most mobile MAT programs. Our mobile health planning and staffing advisory helps programs design substance use treatment programs.
Naltrexone is an opioid antagonist: it blocks the effects of opioids rather than easing withdrawal, and its extended-release injectable form lasts about a month. It carries no risk of misuse, which makes it attractive for some patients, but it requires a person to be fully withdrawn from opioids before starting.
Naltrexone uptake after an overdose is low. In the year after an overdose, only 6% of people received naltrexone, compared with 17% for buprenorphine and 11% for methadone, per the National Institutes of Health. For a mobile program, naltrexone is a useful option for patients who have already achieved abstinence or who prefer a non-agonist, offered alongside buprenorphine rather than in place of it.
Many mobile programs start buprenorphine by offering it the same day as the initial visit, with as few barriers as possible. Low-barrier buprenorphine means starting treatment at the first contact, without requiring prior appointments, counseling attendance, or negative toxicology as a precondition. When someone is ready, the unit begins induction then and there.
This approach matters because starting quickly, before someone leaves, is often the difference between engagement and a missed chance. Programs that want to ground this workflow in local data can use our research and grant services.
The access gap makes mobile MAT valuable because the medication only helps people who can reach a prescriber, and many cannot. As of December 2017, about half of US counties had no buprenorphine prescriber, and nearly a third of rural Americans lived in a county without one, compared with 2.2% of urban Americans, per the NCBI Bookshelf review.
A mobile unit is one of the few ways to put a prescriber into those prescriber deserts without building a permanent clinic in every county. The gap after an overdose is just as stark: in the year after an overdose, fewer than 1 in 3 people got any MOUD, with buprenorphine at 17% and naltrexone at 6%, per the National Institutes of Health. Mobile MAT reaches people at exactly these missed moments. For health plans, mobile units extend access across thin markets that a primary care satellite clinic network cannot cover with fixed sites alone.
Mobile MAT connects patients to ongoing care by treating the unit as the start of a relationship, not a one-time dose. The goal is to stabilize people on medication and then link them to a durable care home: a primary care practice for continued buprenorphine, a specialty program when needed, and social services for housing and food.
Build those connections before launch. That means signed referral agreements, a named contact at each partner, and warm handoffs rather than paper referrals. Staff the program with people hired for the mobile unit rather than fixed-site clinicians on rotation, because patients return for the same faces, and rotating clinicians breaks the continuity that keeps someone on medication. Dedicated staff also protect the program from being the first service cut when a fixed site loses a provider. Our planning and staffing advisory helps build a model that holds.
Yes. Any qualified prescriber can start buprenorphine, and no opioid treatment program license is required, which is why it is the most practical MOUD for mobile programs. Methadone is what requires an opioid treatment program.
Neither is universally better; they suit different patients. Buprenorphine eases withdrawal and cravings and can be started while someone is still using, while naltrexone blocks opioid effects but requires full withdrawal first. Uptake reflects this: after an overdose, 17% of people received buprenorphine versus 6% for naltrexone, per the National Institutes of Health.
Buprenorphine substantially lowers the risk of dying. After an overdose, opioid overdose deaths fell 38% for people on buprenorphine compared with no MOUD over 12 months, per the National Institutes of Health. That protection is why same-visit buprenorphine is worth prioritizing.
Low-barrier buprenorphine means starting treatment at the first contact without requiring prior appointments, mandatory counseling, or negative toxicology as a precondition. The point is to begin medication while the person is ready and present, then build the rest of the care plan around them.
Use dedicated staff, warm handoffs to partners, and peer support specialists who follow up between route stops. Schedule the next visit before the patient leaves and give a direct way to reach the team. Continuity comes from the same trusted staff returning to the same place, which is why hiring for the mobile program matters.
If you want to extend buprenorphine and naltrexone into the communities that have no prescriber, our team can help you design a low-barrier mobile MAT program built to reach people and keep them in care. Learn more about our Behavioral Health Satellite Clinic Network.